Oversubscribed round with proceeds to support continued clinical development

超额认购的融资轮次，所得资金将用于支持持续的临床开发

SAN DIEGO

圣地亚哥

,

，

Aug. 12, 2026

2026年8月12日

/PRNewswire/ -- Amplifica Holdings Group, Inc. ('Amplifica'), a privately held, clinical-stage biopharmaceutical company developing novel therapies for hair growth, today announced the closing of an oversubscribed $26 million Series B Preferred Stock financing. The financing was led by Tasso Partners, LLC, with participation from Eli Lilly and Company, principals of Scopia Capital Management, LP, and other new and existing investors.

/美通社/ -- Amplifica Holdings Group, Inc.（“Amplifica”）是一家私有、临床阶段的生物制药公司，致力于开发新型毛发生长疗法。该公司今日宣布完成一轮超额认购的2600万美元B轮优先股融资。本轮融资由Tasso Partners, LLC领投，礼来公司（Eli Lilly and Company）、Scopia Capital Management, LP的主要负责人以及其他新老投资者参与跟投。

Proceeds will be used to advance clinical development of the Company's novel pipeline candidates, which are designed to reactivate dormant hair follicles and promote the growth of new hair. Currently marketed products are primarily intended to slow or prevent further hair loss..

募集资金将用于推进公司新型管线候选药物的临床开发，这些药物旨在激活休眠的毛囊并促进新发生长。目前市面上销售的产品主要旨在减缓或防止进一步的脱发。

'Closing this oversubscribed round reflects strong investor conviction in the science behind our injectable approach and in the size of the opportunity it addresses,' remarked Frank Fazio, President and CEO. 'This capital allows us to accelerate our mission to deliver next-generation products to patients confronting the physical and emotional challenges of hair loss.'.

“关闭这一超额认购的融资轮次，反映了投资者对我们注射疗法背后的科学原理及其所应对市场机会规模的强烈信心。”总裁兼首席执行官Frank Fazio表示。“这笔资金使我们能够加速推进我们的使命，为面临脱发带来的身心挑战的患者提供下一代产品。”

Androgenetic alopecia is estimated to affect more than 50 million men and 30 million women in the United States. Existing daily-use treatments such as finasteride and minoxidil, though considered the standard of care, have delivered only modest improvements in hair count, and their daily-use profile introduces challenges including poor patient compliance, tolerability and side-effect concerns, and limited efficacy and applicability in women.

据估计，雄激素性脱发在美国影响超过5000万男性和3000万女性。现有的日常使用治疗方法，如非那雄胺和米诺地尔，虽然被视为标准护理方案，但在增加头发数量方面仅带来适度的改善，且其日常使用特性带来了诸多挑战，包括患者依从性差、耐受性和副作用担忧，以及在女性中的疗效和适用性有限。

These ongoing limitations have hindered broader adoption and further underscore the need for innovation in this space..

这些持续存在的限制阻碍了更广泛的采用，并进一步凸显了在该领域进行创新的必要性。

'Amplifica has built a proprietary portfolio of signaling molecules that regulate the hair follicle growth cycle, and this financing advances them further into clinical development,' said Wajdie Ahmad, Co-Founder and Executive Chairman. 'Our discovery platform has yielded candidates that activate follicle regeneration through distinct, complementary mechanisms of action.

“Amplifica 已建立起一个专有的信号分子组合，这些分子可调节毛囊生长周期，而本轮融资将推动它们进一步进入临床开发阶段，”联合创始人兼执行董事长 Wajdie Ahmad 表示。“我们的发现平台已筛选出通过独特且互补的作用机制激活毛囊再生的候选分子。”

Advancing multiple mechanisms in parallel maximizes our probability of clinical success and reinforces our leadership in hair regeneration for men and women.'.

并行推进多种机制，最大限度地提高我们临床成功的概率，并巩固我们在男女毛发再生领域的领导地位。

With this financing, the Company embarks on its next growth phase, focusing its attention on clinical development activities within its injectable product pipeline.

凭借此次融资，公司开启了下一个增长阶段，将重心放在其注射剂产品管线的临床开发活动上。

About Amplifica Holdings Group, Inc.

关于Amplifica Holdings Group, Inc.

Amplifica is a clinical-stage biopharmaceutical company focused on developing novel treatments to address androgenetic alopecia (hair loss), a condition estimated to affect over 50 million men and over 30 million women in the United States alone. The Company is taking a nature-inspired scientific approach using a molecular mechanism that regrows natural hair.

Amplifica 是一家处于临床阶段的生物制药公司，专注于开发新型疗法以应对雄激素性脱发（即脱发），据估计，仅在美国就有超过 5,000 万男性和超过 3,000 万女性受此困扰。该公司采用一种受自然启发的科学方法，利用能够促进自然头发再生的分子机制。

The Company has identified and isolated unique signaling molecules that stimulate hair follicles to regrow hair. Amplifica will be initiating product development programs and clinical trials to evaluate the safety and efficacy of its core technology, as well as obtain all applicable regulatory approvals..

该公司已识别并分离出能够刺激毛囊再生头发的独特信号分子。Amplifica 将启动产品开发计划和临床试验，以评估其核心技术的安全性和有效性，并获得所有适用的监管批准。

For more information, please visit

更多信息，请访问

https://amplificabio.com

https://amplificabio.com

.

。

Forward-Looking Statements

前瞻性陈述

This press release contains 'forward-looking statements' within the meaning of the 'safe harbor' provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as 'anticipate,' 'believe,' 'contemplate,' 'could,' 'estimate,' 'expect,' 'intend,' 'seek,' 'may,' 'might,' 'plan,' 'potential,' 'predict,' 'project,' 'target,' 'aim,' 'should,' 'will,' 'would,' or the negative of these words or other similar expressions.

本新闻稿包含1995年《私人证券诉讼改革法案》“安全港”条款所定义的“前瞻性陈述”。前瞻性陈述可通过使用“预期”、“相信”、“考虑”、“可能”、“估计”、“期望”、“打算”、“寻求”、“可以”、“或许”、“计划”、“潜在”、“预测”、“规划”、“目标”、“旨在”、“应当”、“将”、“将会”等词语，或这些词语的否定形式或其他类似表述来识别。

These forward-looking statements are based on the Company's current beliefs and expectations. Forward-looking statements include, but are not limited to, statements regarding the potential efficacy of the Company's product candidates, the Company's expectations with respect to development and commercialization of the Company's product candidates, the initiation or completion of any future clinical trials.

这些前瞻性陈述基于公司当前的信念和预期。前瞻性陈述包括但不限于，有关公司产品候选物潜在疗效的陈述、公司对产品开发及商业化的预期，以及任何未来临床试验的启动或完成。

Actual results may differ from the forward-looking statements expressed by the Company in this press release, and consequently, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements contained in this announcement are made as of this date, and the Company undertakes no duty to update such information except as required under applicable law..

实际结果可能与本公司在本新闻稿中发表的前瞻性陈述存在差异，因此，您不应将这些前瞻性陈述视为对未来事件的预测。本公告中的前瞻性陈述仅反映截至本日的情况，除非适用法律另有要求，本公司没有义务更新此类信息。

Contact(s)

联系人

Company

公司

[email protected]

[email protected]

Media

媒体

EvolveMKD –

EvolveMKD –

[email protected]

[email protected]

SOURCE Amplifica Holdings Group, Inc.

来源：Amplifica Holdings Group, Inc.

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量

Request a Demo

申请演示